Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02082626 | Study of Eribulin in Children With Cancer to Determine Safety(ERIBULIN) | terminated | Phase 1 | 3 | University of OklahomaOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)(RID) | terminated | Phase 1 | 12 | Yale UniversityOTHER |
| 1 |
| Mar 4, 2020 |
| clinicaltrials |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | terminated | Phase 1 | 2 | Yale UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 35 | ADC Therapeutics S.A.INDUSTRY | 1 | Feb 26, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 | 1 | Northwestern UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP(SMR-3184) | terminated | Phase 1 / Phase 2 | 1 | Allarity TherapeuticsINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT03670888 | A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients | terminated | Phase 1 | 1 | JHL Biotech, Inc.INDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT03119467 | Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 21 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Dec 27, 2019 | clinicaltrials |
| NCT03471351 | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | terminated | Phase 1 | 2 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01445340 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | terminated | Phase 1 / Phase 2 | 22 | Innate PharmaINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02589145 | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02254239 | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | terminated | Phase 1 | 10 | Mayo ClinicOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00691652 | Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) | terminated | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 14, 2019 | clinicaltrials |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 48 | Ashraf BadrosOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01729104 | Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02043860 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma(BMT-02) | terminated | Phase 1 | 3 | University of Illinois at ChicagoOTHER | 1 | Oct 14, 2019 | clinicaltrials |
| NCT01289210 | VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas | terminated | Phase 1 / Phase 2 | 2 | CelgeneINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | terminated | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | terminated | Phase 1 | 2 | Michael ChoiOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | terminated | Phase 1 | 14 | Seagen Inc.INDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia(8400-401) | terminated | Phase 1 / Phase 2 | 31 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 18 | Albert Einstein College of MedicineOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT00372905 | Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 18 | Northwestern UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma | terminated | Phase 1 | 7 | Northwestern UniversityOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT00369629 | Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome | terminated | Phase 1 | 14 | Northwestern UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | terminated | Phase 1 / Phase 2 | 202 | Gilead SciencesINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT00089284 | Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL | terminated | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | terminated | Phase 1 / Phase 2 | 3 | University of California, San DiegoOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 27 | Seagen Inc.INDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT03074825 | Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 5 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | terminated | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | terminated | Phase 1 | 16 | Affimed GmbHINDUSTRY | 4 | Jun 18, 2019 | clinicaltrials |
| NCT00290706 | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 32 | Northwestern UniversityOTHER | 1 | May 28, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2020source: clinicaltrials